Medtide Inc (3880) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of Medtide Inc HK$28.97, price HK$21.52, upside +34.6%, quality 68 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Medtide Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 1, 2026.
How to read this chart
15‑month range HK$18.53 – HK$40.64 · fair‑value band HK$19.62 – HK$38.62 · the HK$21.52 price screens below the HK$28.97 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 1, 2026.
Follow Medtide in your weekly email
Every Wednesday you see whether Medtide is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Medtide Inc., a contract research, development, and manufacturing company, provides early-stage discovery, pre-clinical research, clinical development, and commercial-stage production services. It offers peptide new chemical entity discovery synthesis, manufacturing, and control development and commercial manufacturing services.
Show more
Medtide Inc., a contract research, development, and manufacturing company, provides early-stage discovery, pre-clinical research, clinical development, and commercial-stage production services. It offers peptide new chemical entity discovery synthesis, manufacturing, and control development and commercial manufacturing services. The company focuses on developing oral and/or injectable glucagon, such as peptide-1 (GLP-1) molecule products. Its research and development technology platforms include OmniPeptSynth, PeptiConjuX, PeptiNuclide LinkTech, GreenSynth Innovations, and Impurity Screening. It serves customers in China, the United States, Japan, Europe, South Korea, and Australia. The company was formerly known as Taide Pharmaceutical (Zhejiang) Co., Ltd and changed its name to Medtide Inc. in February 2023. Medtide Inc. was incorporated in 2020 and is headquartered in Hangzhou, China.
Stock analysis
Medtide Inc (3880) currently trades at HK$21.52, while our model-based Fair Value estimate is HK$28.97, implying the stock looks roughly 25.7% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of HK$57.58 per share, and 18 of the 24 models we run sit above the HK$21.52 price.
Bear case: the Asset-Based group reads lowest at HK$8.75, and 6 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: HK$19.62 (bear) to HK$38.62 (bull), the price of HK$21.52 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 68/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Medtide Inc reported revenue of 570M CNY in FY2025 versus 282M CNY in FY2021, a compound +19.2%/yr. Reported net income was 217M CNY in FY2025, compounding +28.3%/yr from FY2021.
Key figures
Market cap HK$3.1B (≈ $389M) · P/E ratio 15.5 · P/S ratio 5.90 · Net margin 38.1% · Return on equity 10.9% · Return on assets (EBIT) 10.7% · Operating margin 29.7% · Revenue (TTM) 551M CNY.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 34% below its 52-week high and 16% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 35%, 3880 screens cheaper than that median.
Fair Value models
Bear HK$19.62Fair Value HK$28.97Bull HK$38.62
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+28.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.6%
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+12.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+12.6%
Dividend (yield on the price)0.0%
2025 sits 303% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+14.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +12.6% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 633 stocks
Beats the industry median on 10/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score68 · Top 25%
Fair Value upside+34.6% · Top 25%
Profitability
Return on equity (TTM)10.9% · Top 25%
Return on assets6.8% · Top 25%
Net margin (TTM)30.7% · Top 25%
Operating margin (TTM)29.7% · Top 25%
Growth and dividend
Revenue growth−7.6% · Below median
Balance sheet
Debt / equity0.40× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Medtide Inc Fair Value". https://www.fairvalue-calculator.com/stock/3880
Frequently asked questions
Is Medtide Inc (3880) overvalued or undervalued?
As of Oct 1, 2026, our model estimates a fair value of HK$28.97 versus a price of HK$21.52, about +35% upside (undervalued).
What is the fair value of 3880?
Our model-based fair value for Medtide Inc is HK$28.97 (as of Oct 1, 2026), built from audited fundamentals. The current price: HK$21.52.
What is the quality score of 3880?
Medtide Inc has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Medtide Inc (3880)?
Our model-based price target is the fair value of HK$28.97 (as of Oct 1, 2026) from 24 valuation models. Cautious scenario HK$19.62, optimistic scenario HK$38.62. It is a calculation from audited fundamentals, not an analyst target.
What is the Medtide Inc stock forecast for 2026?
Our models put fair value at HK$28.97, about +35% upside versus a price of HK$21.52 (undervalued). Cautious scenario HK$19.62, optimistic scenario HK$38.62. The calculation is refreshed regularly with new filings.
What is the revenue of Medtide Inc (3880)?
Medtide Inc reported trailing-twelve-month revenue of about 551M CNY (latest available figure, as of Oct 1, 2026).
What growth is priced into Medtide Inc (3880)?
For today's price to be fair in a discounted-cash-flow model, Medtide Inc would have to grow free cash flow by +14.5 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +19.2 % per year. As of Oct 1, 2026.
What discount rate (WACC) does the fair value of 3880 use?
Our models discount Medtide Inc at 11.8 %: a base by market capitalisation (small), country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Medtide Inc that is +14.5 % per year a year over ten years, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has Medtide Inc (3880) delivered so far?
Over the past 4 years revenue at Medtide Inc grew +19.2 % a year. The price currently implies +14.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Medtide Inc (3880) growing?
The median revenue growth in the sector is +4.4 % a year. That is the yardstick for the growth priced into Medtide Inc (+14.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Medtide Inc (3880)?
The free-cash-flow yield on the price is 5.28 %: that much free cash flow Medtide Inc produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Medtide Inc (3880)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Medtide Inc it is HK$28.97 per share (as of Oct 1, 2026), against a price of HK$21.52. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Medtide Inc stock overvalued or undervalued in 2026?
As of Oct 1, 2026, 3880 trades below its calculated fair value: price HK$21.52, fair value HK$28.97, a gap of about +35% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 3880?
No. The price is what the market pays today (HK$21.52); the fair value is what the company's own numbers justify (HK$28.97). For Medtide Inc the two are HK$7.45 per share apart. That gap is exactly why we show both numbers side by side.
How much is Medtide Inc worth?
The market values Medtide Inc at about HK$3.1B (market capitalisation, as of Oct 1, 2026). Per share that is HK$21.52; our models calculate a fair value of HK$28.97 per share.
What do the bullish and bearish scenarios say about 3880?
Our models span a range for Medtide Inc: cautious scenario HK$19.62, base HK$28.97, optimistic HK$38.62 per share (as of Oct 1, 2026, price HK$21.52). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 3880?
Medtide Inc trades at a price-to-earnings ratio of 15.5 (as of Oct 1, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$28.97 is built from several models across several years. Other multiples: P/B 1.6, P/S 4.7, EV/EBITDA 10.4.
How solid is the balance sheet of Medtide Inc (3880)?
Balance-sheet figures for Medtide Inc (as of Oct 1, 2026): return on equity 10.9%, debt of 0.40 per unit of equity. They feed the Quality Score of 68/100, which measures business quality independently of the share price.
How far is 3880 from its 52-week high?
Medtide Inc trades at HK$21.52, about 34% below its 52-week high of HK$32.74 and 16% above the low of HK$18.53 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of HK$28.97 is for.
Which stocks are comparable to Medtide Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Medtide Inc stock attractive at the current price?
The data as of Oct 1, 2026: price HK$21.52, calculated fair value HK$28.97 (+35%), Quality Score 68/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 3880 calculated?
We run Medtide Inc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$28.97, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. Medtide Inc currently trades 26 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Medtide Inc (3880)?
The closing price on Sep 30, 2026 was HK$21.52. Our model-based fair value is HK$28.97, about +35% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Medtide Inc right now?
Solid quality (68/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (HK$19.62 to HK$38.62) leaves room in how you read the outcome.
Key figures of Medtide Inc
How large is the market capitalisation of Medtide Inc (3880)?
The market capitalisation of Medtide Inc is HK$3.1B (≈ $389M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Medtide Inc (3880)?
The price-to-sales ratio of Medtide Inc is 5.90 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Medtide Inc (3880)?
The net margin of Medtide Inc is 38.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Medtide Inc (3880)?
The return on equity (ROE) of Medtide Inc is 10.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Medtide Inc (3880)?
On an EBIT basis the return on assets of Medtide Inc is 10.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Medtide Inc (3880)?
The operating margin of Medtide Inc is 29.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Medtide Inc (3880)?
Revenue at Medtide Inc is growing −7.6% versus a year earlier (3y avg +17.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Medtide Inc (3880)?
Earnings per share at Medtide Inc are growing −53.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Medtide Inc (3880) carry?
The net debt of Medtide Inc is 41.5M CNY (fiscal year 2022, ≈ 0.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Medtide Inc in the live analysis
One click puts Medtide Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
